title: [The effect of risedronate treatment on bone turnover markers in patients with hip fracture].
abstract: OBJECTIVE
  The effect of risedronate treatment on bone resorption was investigated quantitatively by measuring N-telopeptide levels in urine of patients with hip fracture.
  
  
  METHODS
  Forty-six women (mean age 75 years) who underwent surgical treatment for intertrochanteric or femoral neck fractures due to minor trauma were divided into two groups according to the order of presentation. One group (26 patients; mean age 77+/-5 years) received oral risedronate 5 mg/day after the fifth postoperative day, while the other group (20 patients; mean age 73+/-6 years) received no drug treatment. Patients who had been on treatment for Paget's disease or osteoporosis or those with renal failure were excluded. Urine samples were collected from all the patients on the second day of hospitalization and at the end of three months to measure N-telopeptide levels, one of the bone turnover markers, with the use of the Osteomark NTx ELISA laboratory kit.
  
  
  RESULTS
  The mean urine N-telopeptide level decreased by 49.7% at the end of three months of treatment with risedronate (p<0.0001), whereas there was a 5.8% increase in the N-telopeptide level of the control group. The two groups differed significantly with respect to the levels of bone resorption at the end of three months (p<0.0001).
  
  
  CONCLUSIONS
  Risedronate treatment was found effective in decreasing bone resorption and thus in reducing the risk for refractures in patients with hip fractures due to minor trauma.
authors.affiliation: Department of Orthopedics and Traumatology (Ortopedi ve Travmatoloji Anabilim Dali), Medicine Faculty of Yeditepe University, Istanbul, Turkey. f.altintas@superonline.com
authors.forename: Faik
authors.initials: F
authors.lastname: Altintaş
authors.forename: Afşar Timuçin
authors.initials: AT
authors.lastname: Ozkut
authors.forename: Tahsin
authors.initials: T
authors.lastname: Beyzadeoğlu
authors.forename: Abdullah
authors.initials: A
authors.lastname: Eren
authors.forename: Melih
authors.initials: M
authors.lastname: Güven
mesh_terms: D000284:Administration, Oral; D000368:Aged; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001862:Bone Resorption / Q000517:prevention & control / Q000652:urine; D024042:Collagen Type I / Q000652:urine; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006620:Hip Fractures / Q000150:complications / Q000000981:diagnostic imaging / Q000473:pathology / Q000534:rehabilitation* / Q000601:surgery*; D006801:Humans; D008297:Male; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000652:urine; D010455:Peptides / Q000652:urine; D011859:Radiography; D000068296:Risedronic Acid; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D000068296:Risedronic Acid; D012968:Etidronic Acid